Overview

Efficacy and Safety of HSK392975 in Anti-C5 Treated PNH Patients With Anemia

Status:
RECRUITING
Trial end date:
2026-01-08
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy of HSK39297 tablets in paroxysmal nocturnal hemoglobinuria patients with anemia after stable treatment of anti-C5 antibody.
Phase:
PHASE3
Details
Lead Sponsor:
Haisco Pharmaceutical Group Co., Ltd.